기업 프로필 · Healthcare

Boston Scientific Corp

BSX · 미국
거래소
미국
국가 / 지역
USA
상장일
1992년 5월 18일
직원 수
59,000
현재가
$45.29
실시간 · 2026년 6월 18일
베일리 성장 점수
46/100
다소 약함
내재가치 · 3단계 구간 현재가 $45.29 실시간 · 보수적 구간과 적정 구간 사이

종합 밸류에이션 구간 · 보수적 $31–$40 / 적정 $50–$65 / 낙관적 $80–$95. $45.29 기준, 보수적 구간과 적정 구간 사이.

보고서 발행 시 $57.78(2026년 5월 24일)

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

시가총액US$668.12억
매출 (TTM)US$206.14억
EBITDAUS$55억
순이익률17.29%
ROE14.66%
PER (TTM)18.81
선행 PER13.39
PEG0.54
EPSUS$2.39
52주 범위US$44.80 – US$109.50
애널리스트 목표주가US$77.10
애널리스트 평가4.6 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.